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Abstract
Objectives The effect of different formulations
variables on protein integrity were investigated using
lysozyme as a model protein for the development of
biotherapeutic protein formulations for use in the
clinic.
Results Buffer composition/concentration was the
key variable of formulation reagents investigated in
determining lysozyme stability and authenticity inde-
pendent of protein concentration whilst the storage
temperature and time, not surprisingly, were also key
variables. Tryptic peptide mapping of the protein
showed that the modifications occurred when formu-
lated under specific conditions but not others. A model
peptide system was developed that reflected the same
behavior under formulation conditions as intact
lysozyme.
Conclusions Peptide models may mirror the stability
of proteins, or regions of proteins, in the same
formulations and be used to help develop a rapid
screen of formulations for stabilisation of biothera-
peutic proteins.
Keywords Protein formulation  Mass
spectrometry  Post-translational modification 
Aggregation  Peptide model
Introduction
The number of biopharmaceutical protein-based drugs
on the market and in development continues to
increase with biopharmaceuticals making up a signif-
icant portion of new drugs in the development
pipeline. Protein based drugs are susceptible to
degradation and aggregation (Roberts 2014) that
compromised integrity and as such must be carefully
formulated after their expression and purification at
the appropriate pH, appropriate concentration, in the
appropriate buffers and with appropriate stabilising
excipients to prevent unwanted degradation, modifi-
cation and aggregation events (Mitragotri et al. 2014).
The development of the ‘‘best’’ formulation for a given
biotherapeutic protein to preserve its integrity largely
occurs using a knowledge based, design of experi-
ments trial and error approach using biophysical
methods to determine, amongst other parameters,
how formulation variables influence aggregation and
protein stability (Chaudhuri et al. 2014).
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In order for biopharmaceutical drugs to be success-
ful in clinical applications, appropriate formula-
tion(s) for preservation, stability and delivery need
to be determined. This is not an easy task as each
protein biopharmaceutical is unique and small differ-
ences in the amino acid residues result in the need of a
specific formulation to deliver maximal stability and
activity for each protein. Preservation is usually
investigated using elevated temperature and varying
pH in order to ‘force’ stability issues. Lysozyme,
whilst not a therapeutic protein, is a well-characterised
protein molecular making it a good protein to inves-
tigate the influence of formulation variables on protein
stability and has previously been used for such
purposes (Povey et al. 2009; Smales et al. 2000;
2001). The effect of different formulations variables
on protein integrity were therefore investigated using
lysozyme as a model protein for the development of




All reagents, including egg white lysozyme (L6876-
5G, lyophilized powder) were purchased from Sigma-
Aldrich and were of analytical grade or better.
Plackett–Burman design of experiments
The effect of formulation variables (pH, buffer
composition (mM), time (h), temperature (C), glycine
and NaCl concentration) on lysozyme solubility/
aggregation and activity studies were investigated
using a Plackett–Burman Experimental Design (based
on Zhao et al. 2005) (Supplementary Tables 1 and 2).
Triplicate samples were investigated for each treat-
ment and the mean calculated for data analysis. A two
tailed t test was used to compare the two sample means
i.e. the low and high values of each variable.
Preparation of protein samples in appropriate
formulations
The lysozyme samples (low 0.07 mM and high
0.81 mM) were prepared and then dialyzed against
two changes of the appropriate formulation; one for
2 h and one overnight. After incubation in the
appropriate conditions, samples were centrifuged at
*2009g for 4 min in a Eppendorf centrifuge. The
pellets were carefully separated from the supernatants
and resolubilised in 100 ll 8 M urea/0.25 M Tris/HCl
buffer (pH 8.75)/1 mM EDTA. The concentration of
the initial supernatant and solubilised pellet was
determined by measuring the A280.
Lysozyme activity assays
The activity of lysozyme was measured using Micro-
coccus lysodeikticus as a substrate using the method
previously described (Povey et al. 2007).
Tryptic peptide mapping
Lysozyme samples were subjected to tryptic peptide
mapping using the method previously described
(Smales et al. 2000).
Data analysis
All data was analyzed using the Sequential Design of
Expert tool (EasyStats, DX7, Version 7.1.6) to inves-
tigate and correlate the effect of individual variables
and predict the best formulation conditions for long
term storage at 4 and 25 C.
Liquid chromatography-electrospray ionization
mass spectrometry analysis of intact lysozyme
and tryptic peptides following incubation
in different formulation conditions
Mass spectrometry analysis of the intact lysozyme
samples after incubation in the different formulations
and the tryptic digest samples were undertaken as
previously described (Smales et al. 2000). To identify
potential amino acid modifications a peptide that was
close to the native chicken lysozyme peptide
T12 ? 13 but contained a modification in the third
residue (I at position 3 changed to P) was synthesised
to give a final sequence: SDPTASVNCAK-
KIVSDGNGM (MW: 1992.92 Da). 0.81 mM samples
were prepared in PBS pH 7.3 (used as the stan-
dard/control sample) and formulations 1, 4 and 12
(Supplementary Tables 1 and 2). After incubation in
the appropriate conditions, the pellets were carefully
separated from the supernatants and the pellets
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resolubilized in 100 ll 8 M urea. Samples were
diluted to 2 lg/ll using H2O with 0.05 % TFA and
mass spectrometry analysis undertaken using a
microTOF-Q IITM ESI-qTOF mass spectrometer
(Bruker Daltonic GmbH) coupled to an HPLC. The
analysis and identification of possible modifications to
the peptide was undertaken using the PAWS EXE
protein analysis program (ProteoMetrics) and Delta
Mass database of protein post translational modifica-
tions (http://www.abrf.org/index.cfm/dm.home).
Results and discussion
Quantitative determination of lysozyme solubility
and aggregation in different formulations
All the formulation variables, concentrations and
levels used in this study were based upon those
reported in previous studies (Trikha et al. 2002; Walsh
2006; Wang et al. 2007). The concentration of protein
before and after incubation in solution was determined
by measurement of the A280 (Supplementary Table 3).
The A280 values were measured immediately after
formulation and again after the relevant incubation
time. A decrease in the A280 value and soluble protein
is indicative of aggregation/precipitation of the protein
and loss of protein in solution. Based on previous
studies using a Plackett- Burman approach (Domart-
Coulon et al. 1994; Zhao et al. 2005) if the statistical
significance of a variable was greater than 80 % it was
considered a significant factor.
Significant changes in A280 measurements were
calculated as absolute amounts (mg/ml using extinc-
tion coefficients) and then as a % of the original
compared to a PBS control (Supplementary Table 4).
In all high concentration formulations, less protein
was soluble than in PBS alone and in the case of
formulations 1 and 12 there was a[ 40 % loss in
soluble protein relative to the PBS standard formula-
tion. This was less prevalent in low concentration
formulations although formulations 2 and 3 had
a[ 30 % loss in soluble protein compared to the
control (Supplementary Table 4). The majority of
protein aggregation occurred upon formulation and
not during the following incubation period (Supple-
mentary Table 4). From the A280 analysis and two
tailed t-test statistical testing (Supplementary
Table 4), the buffer composition was found to be
statistically the most significant variable influencing
soluble protein concentration followed by the protein
concentration upon initial formulation. Following
incubation under the different conditions, the most
significant factor in terms of influencing soluble
protein levels was the time of incubation (time of
storage after formulation). Buffer composition was
therefore confirmed as being a key determinant of
aggregation, the formation of which can influence
product performance and must be controlled during
formation of biotherapeutics (Roberts 2014).
The effect of formulation variables on lysozyme
enzymatic activity
Lysozyme initial rate activity was determined by
measuring the OD500 of a suspension of the substrate
Micrococcus lysodeikticus in the presence of lyso-
zyme in each formulation (Fig. 1). (It is noted that the
amount of each sample added to the assays was not
Fig. 1 Absorbance clearing curves of lysozyme samples of
different formulations using the bacterial substrateMicrococcus
Lysodeikticus (n = 3). a Low lysozyme concentration samples,
b High lysozyme concentration samples
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sufficient to change the ionic strength or pH of the
solution, which could influence the observed lyso-
zyme activity.) Most of the formulations had no effect
on lysozyme initial clearing rate activity although the
rates were reduced in formulations 1 and 12 compared
to the standard lysozyme sample in PBS (Fig. 1,
Supplementary Tables 5 and 6). Statistical analysis
showed that buffer composition was the variable with
the greatest influence on the initial rates observed
(Supplementary Table 6).
The equivalent of Vmax and Km of lysozyme
samples in different high concentration formulations
(formulations 1, 4, 8, 9, 10 and 12) was also
determined and the resulting data in Supplementary
Table 7 shows that the protein activity is dramatically
affected by all formulation variables when compared
to the control in PBS. Three of the formulation
conditions (4, 8, 9) showed a small change (decrease)
in initial rate compared to the control but the
maximum clearing rate and concentration of substrate
at  maximum clearing rate were much reduced
compared to the control (Supplementary Table 7). The
formulations that showed the most aggregation by
A280 measurements (formulations 1, 10, and 12)
showed a large drop in initial rate, and the biggest
change (decrease) in the maximum clearing rate and
concentration of substrate at  maximum rate con-
firming that these formulations were detrimental to
enzymatic activity (Supplementary Table 7).
Direct ESI–MS analysis of intact lysozyme
for protein modifications under different
formulation conditions
As shown Fig. 2, a peak that corresponds to that
expected for lysozyme (14,307 Da) was dominant in
the control and formulation 2 samples indicating no
observable and stable modifications occur in this
formulation. In contrast, in the low protein concen-
tration formulations 3, 6 and 11 (Fig. 2c–e) additional
peaks were observed. A peak before the main
lysozyme peak of mass 14,287, 14,287 and 14,286.2
for formulations 3, 6 and 11 respectively was
observed, this loss being prevented in formulation 2.
On the other hand, an additional peak after the main
lysozyme peak of a mass 14,323.0, 14,320.2 and
14,320.5 in formulations 3, 6 and 11 respectively,
corresponds to a gain in mass of 17–20 Da, which
approximately equates to the gain of a water molecule.
Mass spectrometry analysis of lysozyme samples in
formulation 12 showed many changes in mass to the
protein after incubation in this formulation (Fig. 3).
The major peak in the supernatant had a mass of
14,285.2 Da, a loss of 17 compared to the standard
sample, which could to be due to the formation of
pyroglutamic acid formed from Gln or succinimide
formation from asparagine (loss of 17 Da).
Tryptic peptide mapping and reverse-phase
HPLC–ms analysis of lysozyme formulations
In an attempt to analyze and identify any changes and
modifications occurring to lysozyme in under the
different formulation conditions, the supernatants
were directly digested whilst the pellets (i.e. protein
not in solution) were resolubilized by treating with
8 M urea before subsequent tryptic digestion and mass
spectrometry analysis. These samples were compared
to a tryptic digest of lysozyme in formulation 4 and to
a standard protein digest. As shown in Fig. 4, there
were observable changes between the peptide maps of
the supernatants and the pellets after HPLC analysis
separation alone. To identify those modifications that
had occurred within the protein and where they had
occurred, ESI–MS analysis of the tryptic peptides was
undertaken (Fig. 5). Although mass data of good
quality was collected, and each peptide peak could be
assigned due to its mass, positive assignment of
protein modifications proved difficult. While it was
possible to identify the presence of different/extra
peaks in the modified samples compared to the control
samples it was not possible to match a mass to any
known modification. The extra peaks present in
digests consisted of all, or parts of, peptides corre-
sponding to peptides T9, T15, T16, T12 ? 13 and T11
(where T = peptide and the number = the tryptic
peptide as expected from a theoretical tryptic digest
from the N-terminal end of lysozyme (Povey et al.
2009)) and ms/ms analysis revealed that the masses of
these extra peaks were not different from the expected
masses of the peptides (Fig. 5 and Supplementary
Table 8). It is possible that the modifications suppress
the ionization of the modified form of the peptide,
which means it is swamped by the unmodified
material. Despite this, the data suggests it is within
these regions of the protein covering the stretches
within peptides T9, T15, T16, T12 ? T13 and T11
that modification of the protein occurs.
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Mass spectrometry analysis of a model lysozyme
peptide under variable formulation conditions
To be able to further investigate the amino acid
residues that are prone to modification under formu-
lation conditions, a peptide corresponding to residues
T12 ? T13 of chicken lysozyme was synthesized and
incubated under the worst (formulations 1 and 12) and
the best performing (formulation 4) formulations for
the lysozyme samples. The reason for selecting the
peptide from region T12 ? 13 was that this was where
most modifications have previously been observed to
lysozyme under various conditions as reported in the
literature (Smales et al. 2000; Povey et al. 2009).
Further, the data presented above after tryptic peptide
mapping and ESI–MS of the lysozyme samples in the
different formulations also suggested this region of the
protein is prone to modification. This peptide inves-
tigation allowed inspection as to whether such mod-
ifications are simply sequence dependent or whether
they require a structural element.
After incubation or storage of the peptide in the
different formulations for the appropriate time and
temperature indicated, there was no detectable visual
change in the appearance of the peptide in formulation
4. On-the-other-hand, after incubation of the model
peptide in formulations 1 and 12 there was a large
amount of yellow (formulation 1) and white (formu-
lation 12) precipitate observed. After incubation of the
peptide in formulation 1, no evidence of peptide
dimerization as evidenced by the presence of a mass
peak corresponding to a dimer was observed either in
the supernatant or the pellet material (Supplementary
Tables 9 and 10). The most abundant peak was at
1774 Da, a loss of 220 Da from the mass of the full
peptide that equates to the loss of the first and the last
amino acid residues from the peptide (serine and
methionine) (Supplementary Tables 9 and 10). Loss
of a water molecule was also observed in both the
supernatant and the pellet material that is most likely
due to a change to the proline residue (third residue)
that is known to change conformation at high temper-
atures (Lu et al. 2008). Interestingly, after reduction
with DTT both in the supernatant and the pellet a peak
of 1791 Da was observed which equates to a loss of
203 Da from the intact peptide (Supplementary
Table 9). This corresponds to loss of the first two
amino acids in the sequence (serine and aspartic acid)
suggesting that after incubation under these formula-
tion conditions (formulation 1) and temperatures the
Fig. 2 ESI-MS analysis of intact lysozyme under different formulation conditions. a Standard sample in PBS, b Sample formulation 2
supernatant, c Sample formulation 3 supernatant, d Sample formulation 6 supernatant and e Sample formulation 11 supernatant
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peptide bonds can be broken and lead to peptide
degradation.
The most abundant peak after incubation in formu-
lation 12 for both the supernatant and the pellet material
(3987 Da) was twice the expected mass of the peptide
indicating that dimerization had occurred (Supplemen-
tary Table 9). After reduction the peak disappeared
confirming that the dimerizationwas due to the cysteine
residue forming disulphides. The secondmost abundant
peak in both the supernatant and the pellet was the
Fig. 3 ESI–MS analysis of intact lysozyme in formulation 12.
a Standard lysozyme sample in PBS, b representative lysozyme
formulation 12 supernatant sample after incubation in
formulation 12, and c representative lysozyme formulation 12
pellet after incubation and resolubilization in 8 M urea solution
Fig. 4 Separation of
lysozyme samples in
different formulations by
reverse-phase HPLC on a
C18 column after trypic
digestion. a Lysozyme
supernatant samples after
incubation in formulations 1
(red), 4 (blue) and 12
(black), b Lysozyme pellets
samples after incubation in
formulation 1 (red) and 12
(blue) and lysozyme pellet
sample in formulation 12
(black) before incubation
594 Biotechnol Lett (2016) 38:589–596
123
addition of two sodium ions (2037 Da, addition of
43 Da, Supplementary Table 9). After incubation in
formulation 4, although no visual changes were appar-
ent after incubation, the ESI–MS analysis showed the
presence of a dimer peak (3985 Da) that after reduction
with DTT disappeared indicating that this was from
cysteine residue disulphide bond formation (Supple-
mentary Tables 9 and 10).
Conclusions
The buffer composition/concentration was the key
variable of the formulation reagents in determining
lysozyme stability and authenticity independent of
protein concentration whilst the storage temperature
and time, not surprisingly, were also key variables.
Mass changes were observed that differed from the
Fig. 5 ESI–MS analysis of lysozyme in the various formula-
tions after tryptic digestion. The black bar shows the area of
peptide T12 ? 13 (uncleaved peptide), which is known to exist
in several forms. This area in particular shows changes with
formulation suggesting it is susceptible to modification in
agreement with previously published studies. a Formulation 1,
b formulation 4, c formulation 8, d formulation 12 supernatant,
e formulation 12 pellet after incubation and f formulation 12
pellet before incubation. Key List of labelled peaks is on
Supplementary Table 8
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expected mass of lysozyme after incubation in some
formulations that are therefore not suitable for storing
lysozyme. Furthermore, the tryptic peptide mapping
of the protein showed that the modifications occurred
in the regions of the protein covering the stretches
within peptides T9, T15, T16, T12 ? T13 and T11
that have previously been reported to be prone to
modification in the literature (Povey et al. 2009;
Smales et al. 2000). The chicken lysozyme peptide
from residues T12 ? T13 was synthesized and incu-
bated in such unsuitable formulations (formulations 1
and 12) and the best performing (formulation 4). The
behavior of the peptide after incubation reflected the
same behavior as the protein. Further the MS data
showed that under the formulation conditions 1
(alkaline pH, high ionic strength) promoted peptide
degradation while formulation conditions 12 (acidic
pH, low ionic strength) favours dimerization. These
findings suggest that peptide models could be utilized
to mirror the stability of proteins or regions of proteins
in the same formulations and could be used to help
develop a rapid screen of formulations for stabilisation
of troublesome elements and regions within biother-
apeutic proteins.
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